P/E ratio for NRC Health (NRC)
P/E ratio as of April 2024 (TTM): 27.6
According to NRC Health 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 27.6218. At the end of 2022 the company had a P/E ratio of 29.1.
P/E ratio history for NRC Health from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 29.1 | 3.17% |
| 2021 | 28.2 | -2.22% |
| 2020 | 28.9 | -42.62% |
| 2019 | 50.3 | 39.9% |
| 2018 | 36.0 | -47.91% |
| 2017 | 69.1 | 78.14% |
| 2016 | 38.8 | 1.53% |
| 2015 | 38.2 | 20.11% |
| 2014 | 31.8 | -18.91% |
| 2013 | 39.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | -112.07% | Bahamas |
 NRC Health
NRC | 27.6 | 0.00% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.